Interventions for fatigue in Parkinson's disease

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 1, 2014, Pages

  Elbers, Roy G ^a,b   Verhoef, John ^a   van Wegen, Erwin E H ^b   Berendse, Henk W ^b   Kwakkel, Gert ^b  

^a UNIVERSITY OF APPLIED SCIENCES LEIDEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PSYCHOSTIMULANT AGENT;

ARTICLE; COGNITIVE BEHAVIORAL THERAPY; DRUG EFFECT; EXERCISE; FATIGUE; HUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; THERAPY EFFECT;

EID: 85041731481     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD010925     Document Type: Article

References (25)

1. Alves G, Wentzel-Larsen T, Larsen J. Is fatigue an independent and persistent symptom in patients with Parkinson's disease?. Neurology 2004;63:1908-11.
2. Chaudhuri A, Behan P. Fatigue in neurological disorders. Lancet 2004;363:978-88.
3. Cohen J. Statistical Power Analysis in the Behavioral Sciences. 2nd edition. Hillsdale, NJ: Lawrence Erlbaum Associates, Inc., 1988.
4. De Vet H, Terwee C, Knol D, Bouter L. When to use agreement versus reliability measures. Journal of Clinical Epidemiology 2006;60:34-42.
5. Deeks J, Higgins J, Altman D (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
6. Elbers R, Rietberg M, van Wegen E, Verhoef J, Kramer S, Terwee C, et al.Self-report fatigue questionnaires in multiple sclerosis, Parkinson's disease and stroke: a systematic review of measurement properties. Quality of Life Research 2012;21:925-44.
7. Friedman J, Brown R, Comella C, Garber C, Krupp L, Lou J, et al.Fatigue in Parkinson's disease: a review. Movement Disorders 2007;22:297-308.
8. Friedman J, Alves G, Hagell P, Marinus J, Marsh L, Martínez-Martín P, et al.Fatigue rating scales critique and recommendations by the Movement Disorders Society Task Force on rating scales for Parkinson's disease. Movement Disorders 2010;25:805-22.
9. Friedman J, Abrantes A, Sweet L. Fatigue in Parkinson's disease. Expert Opinion on Pharmacotherapy 2011;12:1999-2007.
10. Havlikova E, Rosenberger J, NagyoveI, Middel B, Dubayova T, Gdovinova Z, et al.Impact of fatigue on quality of life in patients with Parkinson's disease. European Journal of Neurology 2008;15:475-80.
11. Herlofson K, Larsen J. Measuring fatigue in patients with Parkinson's disease - the fatigue severity scale. European Journal of Neurology 2002;9:595-600.
12. Herlofson K, Larsen J. The influence of fatigue on health-related quality of life in patients with Parkinson's disease. Acta Neurologica Scandinavica 2003;107:1-6.
13. Higgins J, Altman D, Sterne J (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
14. Higgins J, Deeks (editors). Chapter 7: Selecting studies and collecting data. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
15. Jaeschke R, Singer J, Guyatt G. Measurement of health status. Ascertaining the minimal clinically important difference. Controlled Clinical Trials 1989;10:407-15.
16. Johnston B, Thorlund K, Schünemann H, Xie F, Murad M, Montori V, et al.Improving the interpretation of quality of life evidence in meta-analysis: the application of minimal important difference units. Health and Quality of Life Outcomes 2010;8:116.
17. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
18. Lou J, Dimitrova D, Park B, Johnson S, Eaton R, Arnold G, et al.Using modafinil to treat fatigue in Parkinson disease: a double-blind, placebo-controlled pilot study. Clinical Neuropharmacology 2009;32:305-10.
19. Martínez-Martín P, Catalan M, Benito-León, Ortega Moreno A, Zamarbide I, Cubo E, et al.Impact of fatigue in Parkinson's disease: the fatigue impact scale for daily use (D-FIS). Quality of Life Research 2006;15:597-606.
20. Mendonça D, Menezes K, Jog M. Methylphenidate improves fatigue scores in Parkinson's disease: a randomized controlled trial. Movement Disorders 2007;22:2070-6.
21. Revicki D, Hays R, Cella D, Sloan J. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. Journal of Clinical Epidemiology 2008;61:102-9.
22. Schünemann H, Oxman A, Vist G, Higgins J, Deeks J, Glasziou P, Guyatt G. Chapter 12: Interpreting results and drawing conclusions. In: Higgins J, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. www.cochrane-handbook.org.
23. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox S, Katzenschlager R, et al.The Movement Discorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease. Movement Disorders 2011;26:S42-S80.
24. Terwee C, Jansma E, Riphagen I, de Vet H. Development of a methodological PubMed search filter for finding studies in measurement properties of measurement instruments. Quality of Life Research 2009;18:1115-23.
25. Tyne H, Taylor J, Baker G, Steiger M. Modafinil for Parkinson's disease fatigue. Journal of Neurology 2010;257:452-6.